Biologics Market: Is 2026 the Year "Antibody-Drug Conjugates" (ADCs) Finally End the Era of Toxic Chemotherapy
The year 2026 is being hailed as the "Era of the Smart Bomb" in the Biologics Market. Antibody-Drug Conjugates (ADCs) have become the most sought-after asset in 2026 oncology, combining the "Laser-Focus" of monoclonal antibodies with the "Killing Power" of potent toxins. This 2026 "Guided Missile" approach allows for the destruction of cancer cells while leaving healthy tissue completely...
0 Comments 0 Shares 71 Views 0 Reviews